Amgen (AMGN) updated its FY13 earnings guidance on Wednesday. The company provided earnings per share guidance of $6.85-7.15 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.01. The company issued revenue guidance of $17.8-18.2 billion, compared to the consensus revenue estimate of $17.72 billion.

AMGN has been the subject of a number of recent research reports. Analysts at UBS AG reiterated a buy rating on shares of Amgen in a research note to investors on Wednesday. They now have a $96.00 price target on the stock. On a related note, analysts at Barclays Capital reiterated an equalweight rating on shares of Amgen in a research note to investors on Tuesday. They now have a $90.00 price target on the stock. Finally, analysts at Deutsche Bank reiterated a buy rating on shares of Amgen in a research note to investors on Tuesday. They now have a $108.00 price target on the stock.

Eleven research analysts have rated the stock with a buy rating, two have given an overweight rating, and seventeen have assigned a hold rating to the stock. Amgen presently has an average rating of overweight and an average price target of $94.02.

Amgen (AMGN) traded down 0.26% on Wednesday, hitting $83.07. Amgen (AMGN) has a 52-week low of $65.37 and a 52-week high of $90.81. The stock’s 50-day moving average is currently $87.56. The company has a market cap of $63.744 billion and a price-to-earnings ratio of 14.96.

Amgen last announced its earnings results on Wednesday, January 23rd. The company reported $1.40 earnings per share for the quarter, missing the analysts’ consensus estimate of $1.42 by $0.02. The company had revenue of $4.42 billion for the quarter, compared to the consensus estimate of $4.37 billion. During the same quarter in the prior year, the company posted $1.21 earnings per share. The company’s quarterly revenue was up 11.3% on a year-over-year basis. Amgen has set its FY13 guidance at $6.85-7.15 EPS. On average, analysts predict that Amgen (AMGN) will post $6.50 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which is scheduled for Thursday, March 7th. Investors of record on Wednesday, February 13th will be given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 2.25%. The ex-dividend date of this dividend is Monday, February 11th. This is an increase from Amgen’s previous quarterly dividend of $0.36.

Amgen Inc. (Amgen) is a biotechnology medicines company. The Company discovers, develops, manufactures and markets medicines for illnesses.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.